Recombinant plasmid-hepatocyte growth factor

重组质粒-肝细胞生长因子

Report date: 2025/12/03 09:38:41

Base Information

Drug NameRecombinant plasmid-hepatocyte growth factor
Drug Alias NameAd-HGFPudk-HGF
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vector
Mechanisms of ActionHepatocyte growth factor receptor agonists
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsIschemiaPeripheral Arterial Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAcademy Of Military Medical SciencesWuhan Optical Valley Humanwell Biological Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Haitai United Pharmaceutical Technology Development Co LtdHumanwell Healthcare (Group) Co LtdInstitute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences
Inactive CompaniesWuhan Optical Valley Humanwell Biological Pharmaceutical Co Ltd
Active IndicationsIschemiaPeripheral Arterial Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A